Systemic Lupus Erythematosus (SLE) is a disease where the body's immune system attacks its own tissues, causing pain and inflammation. This study is testing a new medicine called deucravacitinib to see if it is safe and works better than a placebo (a fake medicine that has no real effect) for people with moderate to severe SLE.
To join, you must have been diagnosed with SLE for at least 24 weeks and meet certain criteria, like having specific blood tests and symptoms. People with other autoimmune diseases or serious infections cannot participate.
- Study Length: The study requires you to participate for several weeks.
- Visits Needed: You may have to attend multiple visits during the study.
- Risks and Benefits: There might be risks, but you could help discover a new treatment for SLE.
This study could help find a new treatment for SLE, but it's important to talk to your doctor to see if it's right for you.
How understandable was the trial content above?
Hard to understand
Easy to understand